Droperidol (to be branded Xomolix) is a injectable drug, indicated for the prevention and treatment of post-operative nausea and vomiting in adults and, as a second line, in children. It is also indicated for the prevention of nausea and vomiting induced by morphine derivatives during post-operative patient controlled analgesia in adults.
Wilson Totten, ProStrakan’s CEO, said: “The roll-out of Xomolix across Europe further extends ProStrakan’s pan-EU portfolio of products and, importantly, means that we can make this product available in additional countries where we know there to be a substantial level of unsatisfied patient need.”